4598 Share Price Performance
JP¥0
-614.00 (-100.00%)
Price JP¥0
Share Pricen/a
Delta-Fly Pharma, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
4598 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Delta-Fly Pharma, Inc. Key Details
About 4598
- Founded
- 2010
- Employees
- 13
- CEO
- WebsiteView website
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase 1/2 clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. The company was incorporated in 2010 and is headquartered in Tokushima, Japan.
